How AI can help personalise and predict health care
Produced by Niharika Nanda
Edited and mixed by Suresh Pawar
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30-07-2025
- Time of India
Siemens Healthineers expects up to $580 million tariff impact in 2026
Munich: Siemens Healthineers expects U.S. tariffs to have an impact of up to 500 million euros ($578 million) on 2026 results, its finance chief said on Wednesday, after the European Union and U.S. reached a framework trade agreement on Sunday. The German medical technology company estimates a 400-500 million euro hit in the "most realistic case" for the financial year starting in October, CFO Jochen Schmitz told journalists. He flagged a 200-250 million euro net impact from import duties on the current year. In May, the company had said it expected a 300 million euro hit in the second half of 2025. Its Dutch med-tech peer Philips also slashed its estimated tariff impact for this year on Tuesday. The EU-U.S. deal sets out a 15% import tariff on most EU goods from next month, lower than the 30% U.S. President Donald Trump had threatened to apply earlier in July. With 10% tariffs having already been in place, Schmitz said Siemens Healthineers took a 100 million euro hit in the third quarter, the results of which it reported on Wednesday. Over the medium term, Schmitz said he believed the company would be able to "manage away" all tariff effects. "That will be a combination partly of pricing, but also value-add structure changes under certain circumstances," he said. However, he added that it was too early to make structural decisions as many aspects of the tariff deal were still unclear. Siemens Healthineers also cited the tariff deal when slightly raising its full-year outlook. It expects annual comparable revenue growth of 5.5% to 6%, after previously guiding for 5-6%, and adjusted basic earnings of 2.30-2.45 euros per share, versus 2.20-2.50 euros expected in May. Its revenue was 5.66 billion euros in the third quarter, slightly above analysts' consensus. The company's shares were up 1.6% in Frankfurt as of 0835 GMT.
Time of India
24-07-2025
- Time of India
Apollo Hospitals, Siemens Healthineers Partner on AI-Driven Liver Disease Research
New Delhi: Apollo Hospitals and healthcare company Siemens Healthineers have announced a research collaboration aimed at advancing innovation in artificial intelligence (AI) and imaging technologies to improve liver disease management . According to the partners, the research will span areas such as quantitative ultrasound imaging and AI-driven clinical solutions. The stated objective is to enhance patient care pathways across the liver disease spectrum—from early detection and risk stratification to monitoring interventions and therapy response. This collaboration is indicated to bring together Apollo's clinical expertise and Siemens Healthineers' technical capabilities to develop solutions focused on early diagnosis, accurate assessment, and precise monitoring, in response to the growing burden of liver diseases in India. Dr. Sangita Reddy, Joint Managing Director - Apollo Hospitals said, 'Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease. Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) , may be underestimated, which poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies. AI-driven disease progression models shall play a pivotal role in early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. This model shall also facilitate precision population health strategies and clinical decision support across care settings.' 'Liver disease is a growing health concern in India; it's crucial to prioritize early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend," said Hariharan Subramanian, Managing Director, Siemens Healthcare, Private Limited.
&w=3840&q=100)
Business Standard
23-07-2025
- Business Standard
Apollo, Siemens collaborate to advance liver healthcare with AI innovation
Apollo Hospitals and Siemens Healthineers on Wednesday announced a research collaboration founded on a shared ambition to advance innovations in artificial intelligence (AI) and imaging technologies, with the goal of improving lives. The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes—from early detection and risk stratification to monitoring intervention and therapy response. The partnership combines technical and clinical expertise to develop innovative healthcare solutions for the growing burden of liver diseases in India, with a focus on early diagnosis, accurate detection, and precise monitoring to improve patient outcomes. As per Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), referred to as NAFLD in the report, is a growing cause of liver disease in India. Its prevalence ranges from 9 per cent to 32 per cent and is higher among individuals who are overweight, obese, or have diabetes. According to NFHS-4 (2015–2016), 18–20 per cent of adults are overweight or obese and 3–8 per cent have abnormal blood sugar levels. MASLD significantly increases cardiovascular risk, with heart disease being the leading cause of death. 'At Apollo, we believe that the future of healthcare lies at the intersection of clinical excellence and cutting-edge technology anchored in patient centricity. Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease. Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD may be underestimated. This poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies,' said Sangita Reddy, joint managing director, Apollo Hospitals. 'AI-driven disease progression models will play a pivotal role in the early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. These models will also facilitate precision population health strategies and clinical decision support across care settings. This partnership reflects Apollo's pioneering vision to embed intelligent systems across the clinical spectrum that enable faster, more accurate diagnoses and proactive patient management,' she added. 'Liver disease is a growing health concern in India. It's crucial to prioritise early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend. We believe that advanced technologies will aid timely and precise diagnosis, leading to better disease management and improved quality of life for patients. Our joint effort will help address the unmet needs in liver disease diagnosis and treatment, and we look forward to a fruitful partnership,' said Hariharan Subramanian, managing director, Siemens Healthcare. Following the 2024 memorandum of understanding, the Master Research Agreement (MRA) was formalised in March 2025, establishing a foundation for collaborative research in diagnostic and interventional ultrasound imaging. The signing ceremony for the MRA addendum was held on July 23, 2025, in Hyderabad, marking a significant milestone in this partnership.
